Liquidia Technologies, Abbott to develop siRNA Therapeutics

January 7, 2009: Liquidia Technologies, Inc. has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia’s PRINT (Pattern Replication In Non-wetting Templates) technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

January 7, 2009: Microfluidics, a supplier of advanced fluid processing equipment and reaction technology for the formulation and manufacture of nanomaterials and nanoscale products; and HORIBA Instruments, Inc., maker of analytical instrumentation and measurement technology, announced that their long standing partnership has been formalized. Previously, the two companies have shared marketing efforts, such as seminars and joint customer presentations. From this point forward, these efforts also will include shared exhibit booths at trade shows and exhibitions, and joint advertising and lead generation.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.